An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Esketamine (Primary)
- Indications Depression; Major depressive disorder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SUSTAIN-3
- Sponsors Janssen Research & Development; Janssen-Cilag
- 28 Jul 2017 Planned End Date changed from 31 Dec 2024 to 30 May 2025.
- 11 Jul 2016 Planned End Date changed from 1 Aug 2021 to 1 Dec 2024.
- 30 Jun 2016 Status changed from not yet recruiting to recruiting.